Novel Antimalarial Compounds Targeting Parasite Lifecycle Stages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial and cryptosporidiosis treatments are limited in efficacy and face growing resistance, with existing drugs like chloroquine and nitazoxanide showing partial effectiveness and limitations in targeting various stages of the parasites, particularly the liver and transmission stages of malaria, and inadequate response in immunocompromised patients.
Innovation Solution
Development of novel compounds with specific structures, such as those represented by formulas (I), (II), (III), and (IV), which are used in pharmaceutical compositions to treat or prevent parasitic diseases like malaria and cryptosporidiosis, targeting multiple stages of the parasites and potentially overcoming drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antimalarial drugs like chloroquine and atovaquone are used, then treatment of asexual blood stage malaria is effective, but drug resistance develops and liver-stage and transmission-stage parasites are not targeted
Solution Approach 1:
The patent describes compounds that can target multiple stages of the malaria parasite lifecycle including liver-stage, asexual blood stage, and transmission-stage parasites. This multi-functional capability allows a single compound to address various parasite forms that previously required different drugs, thereby improving both treatment effectiveness and coverage of parasite stages.
Solution Approach 2:
The patent addresses different parasite stages (liver-stage, asexual blood stage, transmission-stage) as separate targets that require specific therapeutic intervention. By designing compounds that can selectively target each stage, the invention provides segmented approach to treating the complex lifecycle of malaria parasites, overcoming the limitation of single-stage targeting by current drugs.
2Reliability
If nitazoxanide is used for cryptosporidiosis, then some treatment effect is achieved, but efficacy is partial in children and no more effective than placebo in patients with AIDS
Solution Approach 1:
The patent describes novel compounds with modified chemical structures (formulas I, II, III, and IV) that differ from nitazoxanide in key structural parameters. These parameter changes in molecular structure are intended to improve pharmacological activity and clinical efficacy, particularly in populations where nitazoxanide shows limited effectiveness such as children and immunocompromised patients.
3Ease of operation
If existing antimalarial drugs are used, then treatment of symptomatic blood stage malaria is possible, but prophylaxis and transmission-blocking are insufficient
Solution Approach 1:
The patent describes compounds capable of providing multiple functions: treatment of symptomatic malaria, prophylaxis against infection, and blocking of transmission to mosquitoes. This multi-functionality allows the same compound to be used for prevention and treatment across different parasite stages, improving prophylactic and transmission-blocking efficacy while maintaining operational simplicity.
Data Source
AI summary
Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including malaria and cryptosporidiosis.